Skip to main content
Fig. 5 | Lipids in Health and Disease

Fig. 5

From: SRT3025-loaded cell membrane hybrid liposomes (3025@ML) enhanced anti-tumor activity of Oxaliplatin via inhibiting pyruvate kinase M2 and fatty acid synthase

Fig. 5

3025@ML enhanced anti-tumor activity of OXA. T24 cells and 5637 cells were treated with 3025@ML, OXA, or the com by reducing PKM2 and FASN bination to verify 3025@ML enhanced anti-tumor activity of OXA by CCK8 analysis (A and B) and trypan blue staining (C and D). This combination therapy significantly reduced cell viability and induced cell death. Annexin V/PI staining (E) supported combination therapy enhances the percentage of cell apoptosis. (F) Treating the cells with OXA or OXA + 3025@ML caused the downregulation of PKM2, AKT, and mTOR and the decrease of p-AKT and p-mTOR levels. (G) Quantitative analysis of the PKM2, FASN, p-AKT, and p-mTOR proteins. *P<0.05

Back to article page

Lipids in Health and Disease

ISSN: 1476-511X